Patents Examined by Andrea K McCollum
-
Patent number: 10383928Abstract: A polypeptide comprising the sequence of SEQ. ID NO. 2, 3, 4, 7 or 8. The polypeptide may have the sequence of an immunogenic fragment thereof comprising at least eight amino acids, wherein the immunogenic fragment is not one of SEQ. ID NOS. 6 or 11 to 16. The polypeptide may have a sequence having at least 80% sequence identity to the aforementioned polypeptide or immunogenic fragment. The polypeptide is less than 100 amino acids in length and does not comprise the sequence of any of SEQ. ID NOS. 10, 46, 56, 57 or 59 to 62 and does not consist of the sequence of SEQ ID NO. 58. The polypeptide is useful in the treatment or prophylaxis of cancer.Type: GrantFiled: April 27, 2017Date of Patent: August 20, 2019Assignee: ULTIMOVACS ASInventors: Gustav Gaudernack, Anne-Marie Rasmussen, Else Marit Inderberg Suso
-
Patent number: 10349640Abstract: The present invention provides a prophylactic or therapeutic agent for a kidney disease, comprising Apoptosis Inhibitor of Macrophage (AIM) or a partial peptide thereof, or a nucleic acid comprising a base sequence encoding the same, or a screening method for a prophylactic or therapeutic agent for a kidney disease, comprising using an animal obtained by subjecting a non-human mammal deficient in AIM expression to unilateral ureteral obstruction or transient kidney ischemia/reperfusion and the like.Type: GrantFiled: February 6, 2015Date of Patent: July 16, 2019Inventor: Toru Miyazaki
-
Patent number: 10342849Abstract: Compositions and methods for treating infectious diseases produced by biofilms are disclosed. More specifically, the present disclosure refers to a pharmaceutical composition which may be used for treating biofilm infections, specifically, biofilms formed by bacteria such as Pseudomonas, E. coli, Klebsiella, and other human pathogens. Pharmaceutical compositions may include a nutrient dispersion that can include sodium citrate, succinic acid, xylitol, glutamic acid, and ethylenediaminetetraacetic acid (EDTA), among others. Additionally disclosed pharmaceutical composition may include active pharmaceutical ingredients (API) such as antibiotics. Subsequently, the antibiotics agent may be ciprofloxacin, amikacin, tobramycin, colistin methate, or polymixin, among others. Pharmaceutical compositions disclosed may employ chemotactic agents in order to disrupt biofilms and therefore enhance the antibiotic response.Type: GrantFiled: June 10, 2016Date of Patent: July 9, 2019Assignee: Professional Compounding Centers of America (PCCA)Inventor: Andrew B. Glasnapp
-
Patent number: 10344084Abstract: An Interleukin-17 (IL-17) binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.Type: GrantFiled: August 11, 2017Date of Patent: July 9, 2019Assignee: Novartis AGInventors: Franco E. Di Padova, Hermann Gram, Hans Hofstetter, Margit Jeschke, Jean-Michel Rene Rondeau, Wim Van Den Berg
-
Patent number: 10265258Abstract: The invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.Type: GrantFiled: August 4, 2017Date of Patent: April 23, 2019Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Angela M. Christiano, Raphael Clynes
-
Patent number: 10259866Abstract: Provided are TAR DNA-binding protein of 43 kDa (TDP-43)-specific binding molecules including polypeptides such as human antibodies, as well as fragments, derivatives and variants thereof. Also provided are methods related to these TDP-43 specific binding molecules. Assays, kits, and solid supports related to TDP-43-specific binding molecules, including polypeptides such as, human antibodies are also disclosed. The TDP-43-specific binding molecule, antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for TDP-43 targeted immunotherapy and diagnosis, respectively.Type: GrantFiled: November 4, 2016Date of Patent: April 16, 2019Assignees: Biogen International Neuroscience GmbH, University of ZürichInventors: Roger Nitsch, Christoph Hock, Maria Grazia Barenco Montrasio, Fabio Montrasio, Jan Grimm, Jean-Luc Baeriswyl, Paul Weinreb, Janaky Coomaraswamy, Omar Quintero-Monzon
-
Patent number: 10251933Abstract: The disclosure relates to therapeutic proteins and pharmaceutical compositions comprising said proteins, which have utility in treating various human diseases. In particular aspects, the disclosed therapeutic proteins are useful for treating human gastrointestinal inflammatory diseases and gastrointestinal conditions associated with decreased epithelial cell barrier function or integrity. Further, the disclosed therapeutic proteins are useful for treating human inflammatory bowel disease, including inter alia, Crohn's disease and ulcerative colitis.Type: GrantFiled: April 6, 2018Date of Patent: April 9, 2019Assignee: Second Genome, Inc.Inventors: Andrew Wonhee Han, Andrew Whitman Goodyear, Tarunmeet Gujral, Todd Zachary Desantis, Karim Dabbagh, Toshihiko Takeuchi, Ye Jin, Michi Izumi Willcoxon, Stefanie Banas
-
Patent number: 10227414Abstract: Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and deriviatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.Type: GrantFiled: May 22, 2017Date of Patent: March 12, 2019Assignee: Amgen Inc.Inventors: Dirk E. Smith, Ian Foltz, Chadwick T. King, Ai Ching Lim, Rutilio Clark, Michael R. Comeau, Randal R. Ketchem, Donghui Shi, Xiaoshan Min, Zhulun Wang
-
Patent number: 10214575Abstract: A method of purifying a Growth Factor Protein in a purification sequence employing chromatography is provided. The method comprises performing at least one chromatography step using a multimodal resin, binding the Growth Factor Protein to the multimodal resin at a pH from 4 to 6.2, and eluting the Growth Factor Protein at a pH in the range of from 5.5 to 6.5. The elution of Growth Factor Protein is improved by addition of arginine and/or NaCl in the eluting buffer. Optionally the multimodal resin step is followed by a yeast derived affinity ligand resin step, which results in a purity of the product greater than 90%.Type: GrantFiled: September 2, 2016Date of Patent: February 26, 2019Assignee: OCTAPHARMA AGInventors: Gustav Gilljam, Stefan Winge, Maya Tiemeyer
-
Patent number: 10195253Abstract: Methods and compositions for treating tumors, especially skin tumors, by locally administering single doses of tumor necrosis factor alpha (TNF?) and interleukin-2 (IL2) at the tumor site, where the TNF? and IL2 are delivered as immunoconjugates comprising an antibody targeted to a splice isoform of an extracellular matrix component such as fibronectin.Type: GrantFiled: June 29, 2012Date of Patent: February 5, 2019Assignee: PHILOGEN S.P.A.Inventor: Kathrin Schwager
-
Patent number: 10172920Abstract: Provided herein is technology relating to treating sleep apnea and particularly, but not exclusively, to treating sleep apnea with immunotherapeutics and/or anti-inflammatory drugs such as beta-interferons and glatiramer acetate.Type: GrantFiled: June 14, 2013Date of Patent: January 8, 2019Assignee: The Regents of The University of MichiganInventors: Tiffany J. Braley, Benjamin Segal, Ronald D. Chervin
-
Patent number: 10137168Abstract: The present invention relates to veterinary decorin compositions and methods of their production.Type: GrantFiled: April 22, 2014Date of Patent: November 27, 2018Assignee: CATALENT PHARMA SOLUTIONS, LLCInventor: Gregory T. Bleck
-
Patent number: 10125181Abstract: A thermostable human epidermal growth factor-spider venom fusion protein with increased skin cell proliferation effect has the amino acid sequence of SEQ ID NO: 2, a gene of E. coli codon-optimized nucleotide sequence of SEQ ID NO: 1 for encoding the human epidermal growth factor-spider venom fusion protein, a recombinant vector including the gene, a host cell transformed with the recombinant vector, and a method for producing in a host cell a human epidermal growth factor-spider venom fusion protein by transforming a host cell with the recombinant vector, and a cosmetic composition for improving skin wrinkle and maintaining skin elasticity including a human epidermal growth factor-spider venom fusion protein, and as the cosmetic composition has excellent thermostability and has an effect of enhancing the activity of improving skin wrinkle and maintaining skin elasticity, it can be advantageously used in future in the field of cosmetics or cosmetic plastic surgery.Type: GrantFiled: July 22, 2016Date of Patent: November 13, 2018Assignees: NEXGEN BIOTECHNOLOGIES, INCInventors: Sun Kyo Lee, Han Bong Ryu, Seong Ran Lee, Jong Nam Choi, Tae Hyun Kim, Tae Won Choi, Tae Hwa Jeong, Hyeong Il Kwon
-
Patent number: 10114028Abstract: Ghrelin signal peptide fragment assays and kits useful in the diagnosis, prognosis, risk stratification, assessing, staging, monitoring, categorizing and determination of further diagnoses and treatment regimens in subjects with various disorders, diseases and conditions including, pneumonia, heart failure, or pneumonia and heart failure or suspected pneumonia, heart failure, or pneumonia and heart failure, and methods for monitoring treatment.Type: GrantFiled: March 15, 2013Date of Patent: October 30, 2018Assignee: Upstream Medical Technologies LimitedInventors: Christopher Joseph Pemberton, Arthur Mark Richards, Matthew Simon Byers
-
Patent number: 10106606Abstract: The current invention relates to procoagulant fusion proteins, polynucleotides that encode said fusion proteins and cells that expresses said fusion proteins. Furthermore, the current invention relates to fusion proteins for use as a medicament. Individuals that have a coagulopathy, such as haemophilia A and B with or without inhibitors, may be treated with fusions proteins of the current invention.Type: GrantFiled: April 4, 2016Date of Patent: October 23, 2018Assignee: Novo Nordisk A/SInventors: Ida Hilden, Lars Christian Petersen, Jens Breinholt, Mette Dahl Andersen, Jais Rose Bjelke, Thomas Egebjerg, Jes Thorn Clausen, Susanne Nedergaard Grell
-
Patent number: 10106855Abstract: The presently disclosed subject matter provides a genetic assay to determine the prognosis in Polycythemia Vera (PV) patients with an indolent form of PV. This assay involves measuring certain messenger RNAs (mRNAs) in blood cells, such as white blood cells. In some embodiments, the cells are CD34+ cells. These mRNA levels are inserted into an algorithm that yields a predictive score of the risk of PV in the patient transforming from an indolent form to an aggressive form.Type: GrantFiled: November 8, 2013Date of Patent: October 23, 2018Assignee: The Johns Hopkins UniversityInventors: Jerry L Spivak, Michael Ochs, Michael Considine, Donna Rowley, Alison R Moliterno
-
Patent number: 10101343Abstract: Described herein are antibodies, and antigen-binding fragments thereof, that are specific for folate receptor alpha, related polynucleotides, expression vectors, and cells that express the described antibodies. Also provided are methods of using the described antibodies, and antigen-binding fragments thereof, and related kits. Provided herein are also methods for diagnosing cancers, such as breast cancer, thyroid cancer, colorectal cancer, endometrial cancer, fallopian tube cancer, ovarian cancer, or lung cancer, using the described antibodies, and antigen-binding fragments thereof. The methods involve determining the amount of folate receptor alpha in a sample derived from a subject and comparing this level with the level of folate receptor alpha in a control sample or reference sample.Type: GrantFiled: February 16, 2017Date of Patent: October 16, 2018Assignee: Eisai R&D Management Co., Ltd.Inventor: Daniel John O'Shannessy
-
Patent number: 10098956Abstract: A method for stabilizing a human blood protein or human blood plasma protein with a molecular weight of >10 KDa by adding melezitose to a solution comprising the human blood protein or human blood plasma protein with a molecular weight of >10 KDa.Type: GrantFiled: May 17, 2016Date of Patent: October 16, 2018Assignee: OCTAPHARMA AGInventors: Elsa Ivarsson, Josefin Knutsson, Brita Rippner, Ulrika Nilsson, Irène Agerkvist
-
Patent number: 10081677Abstract: Interleukin-18 (IL-18) participates in both innate and acquired immunity. The bioactivity of IL-18 is negatively regulated by the IL-18 binding protein (IL18BP), a naturally occurring and highly specific inhibitor. This soluble protein forms a complex with free IL-18 preventing its interaction with the IL-18 receptor, thus neutralizing and inhibiting its biological activity. The present invention discloses binding molecules, in particular antibodies or fragments thereof, which bind IL-18 and do not bind IL-18 bound to IL-18BP (IL-18/IL-18BP complex). Apart from its physiological role, IL-18 has been shown to mediate a variety of autoimmune and inflammatory diseases. The binding molecules of the inventions may be used as therapeutic molecules for treating IL-18-related autoimmune and inflammatory diseases or as diagnostic tools for characterizing, detecting and/or measuring IL-18 not bound to IL-18BP as component of the total IL-18 pool.Type: GrantFiled: May 25, 2016Date of Patent: September 25, 2018Assignee: NOVARTIS AGInventors: Michael Otto Bardroff, Barbara Brannetti, Emma Michelle Campbell, Beate Diefenbach-Streiber, Adina Eberth, Christian Carsten Silverster Kunz, Sylwia Marshall, Jean-Michel Rene Rondeau, Jean-Marc Alfred Schlaeppi, Gino Anselmus Van Heeke
-
Patent number: 10066024Abstract: A method of generating an antibody which inhibits a metalloenzyme is disclosed. The method comprises immunizing a subject with: (i) a synthetic zinc mimicry compound having structural and electronic properties similar to a catalytic domain of the metalloenzyme; and (ii) the metalloenzyme, Antibodies generated by this method are also disclosed as well as uses thereof.Type: GrantFiled: October 27, 2011Date of Patent: September 4, 2018Assignee: Yeda Research and Development Co. Ltd.Inventors: Irit Sagi, Netta Sela-Paswell, Moran Grossman